Advances in Antibody-based Treatments for Pain in the United States - Genetic Technology TOE

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends in pain treatment using antibodies in the United States. The corresponding patent scenario is depicted, along with the industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically al

Table of Contents

Advances in Antibody-based Treatments for Pain in the United States - Genetic Technology TOETechnology ProfilesMonoclonal Antibody against Nerve Growth Factor for Pain Management Fully Human Anti-NGF Monoclonal Antibody for Osteoarthritic PainNovel Antibody for Treating Pain and ItchCalcitonin Gene-Related Peptide Antibody for Preventing MigraineAppendixPatent ScenarioPatent ScenarioIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.